A Phase 3 interventional study of Bupivacaine HCl and SKY0402 in Hemorrhoids, sponsored by Pacira Pharmaceuticals, Inc. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-06.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Hemorrhoids with a site in United States — 9 open to participants now, 9 under way, none of them phase 3. Hemorrhoids · United States.
Among the 33 studies in Hemorrhoids with a site in United States, this one is the 3rd largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2008, is one of 2 in phase 3, and was the 4th registered.
239 studies on the registry are indexed under Hemorrhoids; 73 are open to participants now.
Browse Hemorrhoids studies →9 of the 33 studies in Hemorrhoids with a site in United States are open now. Recruiting first, the newest first:
Jessica K. Stewart, MD · Sites in United States
Ages 18–89
Joint & Vascular Institute · Sites in United States
Ages 18+
University of California, Los Angeles · Sites in United States
Ages 18–90
Huntington Memorial Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Hemorrhoids studies recruiting now, 15 (39%) set no upper age limit and 11 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is above the median of 100 across 184 interventional studies indexed under Hemorrhoids.
Median enrollment 83 across the 28 interventional studies, 80 across the 5 observational. Of the 20 that completed or were terminated, 6 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
Pacira BioSciences, Inc. has 2 studies filed under Hemorrhoids — fewer than ten, so there is no comparison to draw.
5 of the studies in Hemorrhoids with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07639853Medtronic EndovascularCase-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils | 2026-11 |
| NCT06106269Mayo ClinicOutcomes and Quality of Life Following Rectal Artery Embolization for Bleeding Internal Hemorrhoids | 2026-12 |
| NCT06625138Huntington Memorial HospitalTrial of Latex vs Non-latex Hemorrhoid Banding | 2026-12-01 |
| NCT04248205University of OklahomaKetamine for Post-operative Analgesia in Hemorrhoidectomy | 2027-01 |
| NCT07161765University of MichiganRectal Evacuation Disorders and Straining-associated Symptoms in Bleeding Hemorrhoids | 2027-05-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 33 studies in Hemorrhoids with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Effective postoperative pain control to promote improved healing, faster patient mobilization, shortened hospital stays, and reduced healthcare costs.
Effective postoperative pain control is a critical element in patient recovery, as the majority of patients may experience significant pain, particularly in the first few days following surgery. Appropriate postoperative pain management contributes to improved healing, faster patient mobilization, shortened hospital stays, and reduced healthcare costs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 mg Bupivacaine HCl (e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402. A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration.
Drug: Bupivacaine HCl
300 mg SKY0402 in a 40-mL injection volume. A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration.
Drug: SKY0402
100 mg Bupivacaine HCl
Also known as: Marcaine with epinephrine 1:200,000
Single administration 300 mg SKY0402 in a 40-mL injection volume
Also known as: DepoBupivacaine
Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores
To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain. The subject was to rest in this position for at least 5 minutes before responding to the following question, "On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain are you having right now?"
Time frame: through 96 hours
Number of Participants With Adverse Events (AEs) Through Day 3 and Serious Adverse Events (SAEs) Through Day 30
Time frame: through day 30
| Milestone | Bupivacaine HCl | SKY0402 |
|---|---|---|
| Started | 103 | 101 |
| Completed | 103 | 101 |
| Not completed | 0 | 0 |
To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain. The subject was to rest in this position for at least 5 minutes before responding to the following question, "On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain are you having right now?"
| Units on a scale*hours | Bupivacaine HCl | SKY0402 |
|---|---|---|
| Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores | 359 ± 194 | 396 ± 213 |
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bupivacaine HCl | — | 1/103 (1%) | 65/103 (63.1%) |
| SKY0402 | — | 1/101 (1%) | 67/101 (66.3%) |
| Event | Bupivacaine HCl | SKY0402 |
|---|---|---|
| Chronic Postop PainGeneral disorders | 0/103 | 1/101 |
| Fecal ImpactionGastrointestinal disorders | 0/103 | 1/101 |
| Bleeding UlcerGastrointestinal disorders | 1/103 | 0/101 |
| Event | Bupivacaine HCl | SKY0402 |
|---|---|---|
| NauseaGastrointestinal disorders | 32/103 | 38/101 |
| ConstipationGastrointestinal disorders | 12/103 | 16/101 |
| VomitingGastrointestinal disorders | 9/103 | 16/101 |
| PyrexiaGeneral disorders | 0/103 | 8/101 |
| HeadacheNervous system disorders | 7/103 | 3/101 |
| FlatulenceGastrointestinal disorders | 2/103 | 5/101 |
| Abdominal PainGastrointestinal disorders | 0/103 | 5/101 |
| PruritisSkin and subcutaneous tissue disorders | 4/103 | 5/101 |
| Urinary RetentionRenal and urinary disorders | 0/103 | 5/101 |
| Age, Categorical(Participants) | Bupivacaine HCl | SKY0402 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 94 | 95 | 189 |
| >=65 years | 9 | 6 | 15 |
| Age Continuous(years) | Bupivacaine HCl | SKY0402 | Total |
|---|---|---|---|
| Mean | 49 ± 11.6 | 50.2 ± 11 | 49.6 ± 11.3 |
| Sex: Female, Male(Participants) | Bupivacaine HCl | SKY0402 | Total |
|---|---|---|---|
| Female | 50 | 48 | 98 |
| Male | 53 | 53 | 106 |
| Region of Enrollment(participants) | Bupivacaine HCl | SKY0402 | Total |
|---|---|---|---|
| United States | 103 | 101 | 204 |
The record gives a start of Aug 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 4 years 6 months after primary completion. A results delay was requested in Aug 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine